Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

NCT06731478 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

726

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer
Gastroesophageal Junction Cancer

Interventions

DRUG: Trastuzumab Deruxtecan
DRUG: pembrolizumab
DRUG: Trastuzumab
DRUG: Chemotherapy

Sponsor

Daiichi Sankyo

Collaborators

[object Object]